These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1341 related articles for article (PubMed ID: 22945416)

  • 1. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
    Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH
    JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.
    Bekhbat M; Chu K; Le NA; Woolwine BJ; Haroon E; Miller AH; Felger JC
    Psychoneuroendocrinology; 2018 Dec; 98():222-229. PubMed ID: 30249443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.
    Weinberger JF; Raison CL; Rye DB; Montague AR; Woolwine BJ; Felger JC; Haroon E; Miller AH
    Brain Behav Immun; 2015 Jul; 47():193-200. PubMed ID: 25529904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
    McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
    JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
    Mehta D; Raison CL; Woolwine BJ; Haroon E; Binder EB; Miller AH; Felger JC
    Brain Behav Immun; 2013 Jul; 31():205-15. PubMed ID: 23624296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT).
    Webers C; Stolwijk C; Schiepers O; Schoonbrood T; van Tubergen A; Landewé R; van der Heijde D; Boonen A
    Arthritis Res Ther; 2020 Sep; 22(1):225. PubMed ID: 32993799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression.
    Lee Y; Mansur RB; Brietzke E; Carmona NE; Subramaniapillai M; Pan Z; Shekotikhina M; Rosenblat JD; Suppes T; Cosgrove VE; Kramer NE; McIntyre RS
    Brain Behav Immun; 2020 Aug; 88():631-639. PubMed ID: 32380271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.
    Nettis MA; Lombardo G; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Sforzini L; Bogdanova A; Cleare A; Young AH; Pariante CM; Mondelli V
    Neuropsychopharmacology; 2021 Apr; 46(5):939-948. PubMed ID: 33504955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adjunctive N-acetylcysteine on depressive symptoms: Modulation by baseline high-sensitivity C-reactive protein.
    Porcu M; Urbano MR; Verri WA; Barbosa DS; Baracat M; Vargas HO; Machado RCBR; Pescim RR; Nunes SOV
    Psychiatry Res; 2018 May; 263():268-274. PubMed ID: 29605103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial.
    Bergfeld IO; Mantione M; Hoogendoorn ML; Ruhé HG; Notten P; van Laarhoven J; Visser I; Figee M; de Kwaasteniet BP; Horst F; Schene AH; van den Munckhof P; Beute G; Schuurman R; Denys D
    JAMA Psychiatry; 2016 May; 73(5):456-64. PubMed ID: 27049915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pentoxifylline for the treatment of bipolar I/II patients with treatment-resistant depression: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
    Mohammad TAM; Mohammad TAM; Shawis TN
    Brain Res Bull; 2024 Oct; 216():111047. PubMed ID: 39128677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
    Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
    Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of a preliminary discontinued double-blind, randomized, placebo-controlled trial of the anti-TNF-α chimeric monoclonal antibody infliximab in complex regional pain syndrome.
    Dirckx M; Groeneweg G; Wesseldijk F; Stronks DL; Huygen FJ
    Pain Pract; 2013 Nov; 13(8):633-40. PubMed ID: 23692303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.
    Rapaport MH; Nierenberg AA; Schettler PJ; Kinkead B; Cardoos A; Walker R; Mischoulon D
    Mol Psychiatry; 2016 Jan; 21(1):71-9. PubMed ID: 25802980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.
    Papakostas GI; Shelton RC; Zajecka JM; Bottiglieri T; Roffman J; Cassiello C; Stahl SM; Fava M
    J Clin Psychiatry; 2014 Aug; 75(8):855-63. PubMed ID: 24813065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.